Jefferies Reiterates Buy Rating on Vaxcyte (PCVX): "adult PCV alone increasingly supports a materially higher long-term valuation"
Tweet Send to a Friend
Jefferies analyst Roger Song reiterated a Buy rating and $146.00 price target on Vaxcyte (NASDAQ: PCVX)The analyst commented, "At a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
